The Experts below are selected from a list of 12234 Experts worldwide ranked by ideXlab platform
Marcello Lanari - One of the best experts on this subject based on the ideXlab platform.
-
chilblains in a child with confirmed sars cov 2 infection a red flag for late onset Skin Manifestation in previously infected individuals
Journal of The European Academy of Dermatology and Venereology, 2021Co-Authors: Iria Neri, Francesca Conti, Annalucia Virdi, Alba Guglielmo, Lucia Leonardi, Ilaria Corsini, Chiara Ghizzi, Liliana Gabrielli, Tiziana Lazzarotto, Marcello LanariAbstract:During the COVID-19 pandemic an outbreak of chilblain lesions has been described worldwide. The relationship with SARS-CoV-2 infection is still debated. Emerging literature regarding this possible correlation focuses on two hypotheses: an endothelial infection or the result of an IFN type I-mediated immune response.
Sarah Ohrndorf - One of the best experts on this subject based on the ideXlab platform.
-
detection of subclinical Skin Manifestation in patients with psoriasis and psoriatic arthritis by fluorescence optical imaging
Arthritis Research & Therapy, 2020Co-Authors: A Schmidt, A M Glimm, I K Haugen, Paula Hoff, G Schmittat, G R Burmester, Jens Klotsche, Sarah OhrndorfAbstract:To investigate the frequency of subclinical Skin inflammation in both hands by fluorescence optical imaging (FOI) in patients with psoriasis/psoriatic arthritis (Pso/PsA) vs. rheumatoid arthritis (RA) and healthy individuals, and to correlate these findings with cardiovascular (CV) risk factors. The FOI scans were analyzed retrospectively to detect clinically invisible Skin enhancement (0–3 scale) in both hands without relationship to underlying joints or blood vessels. We further characterized the FOI patterns and sorted the scans into groups based on the assumed diagnosis (Pso/PsA, RA, and healthy controls), which was compared with the physician’s diagnosis. Furthermore, the associations between CV risk factors and imaging findings were investigated by regression analyses. We included FOI scans of patients with Pso/PsA (n = 80), RA (n = 78), and healthy controls (n = 25). Subclinical Skin enhancement on the back of their hands was more common in Pso/PsA (72.5%) than in RA patients (20.5%) and healthy individuals (28.0%) (p < 0.001). Based on the FOI pattern, the majority of patients with Pso/PsA (72.5%), RA (76.9%), and healthy controls (68.0%) were classified correctly using the physician-based diagnosis as reference (overall agreement of 74%, kappa = 0.57). No CV risk factors except body weight (kg) were associated with subclinical Skin enhancement (OR 1.04, 95% CI 1.02–1.06; p < 0.001). Subclinical subdermal Skin inflammation was common in Pso/PsA patients using FOI. Based on the FOI pattern, most patients with Pso/PsA and were classified with the correct diagnosis. We demonstrated an important influence of the body weight on our FOI results. FOI may be a helpful novel tool to study microcirculation in rheumatic diseases with Skin involvement.
-
op0311 detection of subclinical Skin Manifestation in patients with psoriasis and psoriatic arthritis by fluorescence optical imaging
Annals of the Rheumatic Diseases, 2020Co-Authors: A Schmidt, A M Glimm, Paula Hoff, G Schmittat, G R Burmester, Jens Klotsche, Sarah OhrndorfAbstract:Background: Fluorescence optical imaging (FOI) as new imaging technique enables visualization of an impaired microcirculation in both hands caused by joint inflammation. A detection of psoriatic Skin inflammation which may also signify an altered vessel composition via FOI has not yet been examined. Objectives: The aim of the present study was to investigate potential subclinical Skin inflammation in both hands of psoriasis (Pso) and psoriatic arthritis (PsA) patients in comparison to rheumatoid arthritis (RA) and healthy individuals by FOI, and to correlate these findings with cardiovascular risk factors or events, since a connection to Psoriasis Skin involvement is assumed. Methods: FOI scans of patients with Pso and PsA as well as RA and healthy subjects were analyzed retrospectively to detect subclinical Skin enhancement in both hands that did not clinically show overt psoriasis Skin changes. According to the ‘fluorescence optical imaging activity score’ (FOIAS) (1) used for evaluation of joint enhancement so far, a standardized definition was set in order to describe the degree of Skin enhancement via a semi-quantitative (0-3) score (see Figure). The score was applied for the first third of the FOI exam sequence (0-120 sec.). To be scored as potential subdermal Skin enhancement, it had to be localized on the back of the hands without relationship to an underlying joint or blood vessel since the ICG enhancement was then most likely localized in the area of the (sub)dermis. Using this analysis method, we further characterized the patterns and sorted the scans into the groups PsA/Pso, RA and healthy controls to compare these with the final physician’s diagnosis. Furthermore, cardiovascular risk factors (e.g. obesity, smoking status, hypertension) were collected and correlated to imaging findings. Results: We included FOI scans of patients with PsA/Pso (n=80), patients with RA (n=78) and healthy controls (n=25). Significantly more PsA/Pso patients showed subclinical Skin enhancement on the back of their hands than RA and healthy individuals (PsA/Pso: 72.5%, RA: 20.5%, healthy controls: 28.0%; p Conclusion: We were able to proof our primary hypothesis that it is possible to visualize subclinical subdermal Skin inflammation in PsA/Pso patients using FOI. Furthermore, we were also able to categorize PsA/Pso and RA patients correctly by using our newly developed method. Although we could not establish a correlation between subdermal Skin enhancement and cardiovascular risk factors, we demonstrated an important influence of the body weight on our FOI results. FOI may be a helpful novel tool to study microcirculation in rheumatic diseases with Skin involvement. References: [1]Werner SG, et al. Inflammation assessment in patients with arthritis using a novel in vivo fluorescence optical imaging technology. Ann Rheum Dis. 2012;71(4):504-10. Disclosure of Interests: Angelique Schmidt Speakers bureau: Speakers fee from Novartis, Roche, Abbvie, BMS, Anne-Marie Glimm: None declared, Paula Hoff: None declared, Gabriela Schmittat: None declared, Gerd Rudiger Burmester Consultant of: AbbVie Inc, Eli Lilly, Gilead, Janssen, Merck, Roche, Pfizer, and UCB Pharma, Speakers bureau: AbbVie Inc, Eli Lilly, Gilead, Janssen, Merck, Roche, Pfizer, and UCB Pharma, Jens Klotsche: None declared, Sarah Ohrndorf: None declared
Iria Neri - One of the best experts on this subject based on the ideXlab platform.
-
chilblains in a child with confirmed sars cov 2 infection a red flag for late onset Skin Manifestation in previously infected individuals
Journal of The European Academy of Dermatology and Venereology, 2021Co-Authors: Iria Neri, Francesca Conti, Annalucia Virdi, Alba Guglielmo, Lucia Leonardi, Ilaria Corsini, Chiara Ghizzi, Liliana Gabrielli, Tiziana Lazzarotto, Marcello LanariAbstract:During the COVID-19 pandemic an outbreak of chilblain lesions has been described worldwide. The relationship with SARS-CoV-2 infection is still debated. Emerging literature regarding this possible correlation focuses on two hypotheses: an endothelial infection or the result of an IFN type I-mediated immune response.
A Schmidt - One of the best experts on this subject based on the ideXlab platform.
-
detection of subclinical Skin Manifestation in patients with psoriasis and psoriatic arthritis by fluorescence optical imaging
Arthritis Research & Therapy, 2020Co-Authors: A Schmidt, A M Glimm, I K Haugen, Paula Hoff, G Schmittat, G R Burmester, Jens Klotsche, Sarah OhrndorfAbstract:To investigate the frequency of subclinical Skin inflammation in both hands by fluorescence optical imaging (FOI) in patients with psoriasis/psoriatic arthritis (Pso/PsA) vs. rheumatoid arthritis (RA) and healthy individuals, and to correlate these findings with cardiovascular (CV) risk factors. The FOI scans were analyzed retrospectively to detect clinically invisible Skin enhancement (0–3 scale) in both hands without relationship to underlying joints or blood vessels. We further characterized the FOI patterns and sorted the scans into groups based on the assumed diagnosis (Pso/PsA, RA, and healthy controls), which was compared with the physician’s diagnosis. Furthermore, the associations between CV risk factors and imaging findings were investigated by regression analyses. We included FOI scans of patients with Pso/PsA (n = 80), RA (n = 78), and healthy controls (n = 25). Subclinical Skin enhancement on the back of their hands was more common in Pso/PsA (72.5%) than in RA patients (20.5%) and healthy individuals (28.0%) (p < 0.001). Based on the FOI pattern, the majority of patients with Pso/PsA (72.5%), RA (76.9%), and healthy controls (68.0%) were classified correctly using the physician-based diagnosis as reference (overall agreement of 74%, kappa = 0.57). No CV risk factors except body weight (kg) were associated with subclinical Skin enhancement (OR 1.04, 95% CI 1.02–1.06; p < 0.001). Subclinical subdermal Skin inflammation was common in Pso/PsA patients using FOI. Based on the FOI pattern, most patients with Pso/PsA and were classified with the correct diagnosis. We demonstrated an important influence of the body weight on our FOI results. FOI may be a helpful novel tool to study microcirculation in rheumatic diseases with Skin involvement.
-
op0311 detection of subclinical Skin Manifestation in patients with psoriasis and psoriatic arthritis by fluorescence optical imaging
Annals of the Rheumatic Diseases, 2020Co-Authors: A Schmidt, A M Glimm, Paula Hoff, G Schmittat, G R Burmester, Jens Klotsche, Sarah OhrndorfAbstract:Background: Fluorescence optical imaging (FOI) as new imaging technique enables visualization of an impaired microcirculation in both hands caused by joint inflammation. A detection of psoriatic Skin inflammation which may also signify an altered vessel composition via FOI has not yet been examined. Objectives: The aim of the present study was to investigate potential subclinical Skin inflammation in both hands of psoriasis (Pso) and psoriatic arthritis (PsA) patients in comparison to rheumatoid arthritis (RA) and healthy individuals by FOI, and to correlate these findings with cardiovascular risk factors or events, since a connection to Psoriasis Skin involvement is assumed. Methods: FOI scans of patients with Pso and PsA as well as RA and healthy subjects were analyzed retrospectively to detect subclinical Skin enhancement in both hands that did not clinically show overt psoriasis Skin changes. According to the ‘fluorescence optical imaging activity score’ (FOIAS) (1) used for evaluation of joint enhancement so far, a standardized definition was set in order to describe the degree of Skin enhancement via a semi-quantitative (0-3) score (see Figure). The score was applied for the first third of the FOI exam sequence (0-120 sec.). To be scored as potential subdermal Skin enhancement, it had to be localized on the back of the hands without relationship to an underlying joint or blood vessel since the ICG enhancement was then most likely localized in the area of the (sub)dermis. Using this analysis method, we further characterized the patterns and sorted the scans into the groups PsA/Pso, RA and healthy controls to compare these with the final physician’s diagnosis. Furthermore, cardiovascular risk factors (e.g. obesity, smoking status, hypertension) were collected and correlated to imaging findings. Results: We included FOI scans of patients with PsA/Pso (n=80), patients with RA (n=78) and healthy controls (n=25). Significantly more PsA/Pso patients showed subclinical Skin enhancement on the back of their hands than RA and healthy individuals (PsA/Pso: 72.5%, RA: 20.5%, healthy controls: 28.0%; p Conclusion: We were able to proof our primary hypothesis that it is possible to visualize subclinical subdermal Skin inflammation in PsA/Pso patients using FOI. Furthermore, we were also able to categorize PsA/Pso and RA patients correctly by using our newly developed method. Although we could not establish a correlation between subdermal Skin enhancement and cardiovascular risk factors, we demonstrated an important influence of the body weight on our FOI results. FOI may be a helpful novel tool to study microcirculation in rheumatic diseases with Skin involvement. References: [1]Werner SG, et al. Inflammation assessment in patients with arthritis using a novel in vivo fluorescence optical imaging technology. Ann Rheum Dis. 2012;71(4):504-10. Disclosure of Interests: Angelique Schmidt Speakers bureau: Speakers fee from Novartis, Roche, Abbvie, BMS, Anne-Marie Glimm: None declared, Paula Hoff: None declared, Gabriela Schmittat: None declared, Gerd Rudiger Burmester Consultant of: AbbVie Inc, Eli Lilly, Gilead, Janssen, Merck, Roche, Pfizer, and UCB Pharma, Speakers bureau: AbbVie Inc, Eli Lilly, Gilead, Janssen, Merck, Roche, Pfizer, and UCB Pharma, Jens Klotsche: None declared, Sarah Ohrndorf: None declared
Ichiro Katayama - One of the best experts on this subject based on the ideXlab platform.
-
abberant sudomotor functions in sjogren s syndrome comparable study with atopic dermatitis on dry Skin Manifestation
Current problems in dermatology, 2016Co-Authors: Ichiro KatayamaAbstract:This chapter summarizes recent advances in the pathogenesis and management of Sjogren's syndrome (SS). Major topics are newly described pathomechanisms and cutaneous Manifestations of SS, with special references to hypohidrosis and related mucocutaneous Manifestations. Although the significance of cutaneous Manifestations in SS has been gradually recognized in rheumatologists, sudomotor function has not been fully evaluated and recognized in the diagnosis of SS except by dermatologists. SS is a relatively underestimated collagen disease in contrast to systemic lupus erythematosus, systemic sclerosis, or dermatomyositis, and special care is needed not to misdiagnose SS when we see patients with common Skin diseases such as drug eruption, infectious Skin disease, or xerosis in daily practice. In contrast to SS, the reduced sweating function seen in atopic dermatitis (AD) is restricted only to axon reflex-induced indirect sweating, which is usually restored to normal levels after improvement of the dermatitis. Therefore, the xerotic Skin lesions seen in SS and AD might be attributable to different pathomechanisms with similar dry Skin Manifestations. It is well known that dry Skin is occasionally seen in SS, and clinical use of muscarinic M3-receptor agonists occasionally improves this condition through recovery of sweating function. Therefore, this M3-receptor agonist might be a promising drug and should be evaluated for the treatment of impaired sweating in AD complicated with or without SS.
-
Annular erythema associated with Sjögren’s syndrome: review of the literature on the management and clinical analysis of Skin lesions
Modern Rheumatology, 2010Co-Authors: Ichiro Katayama, Yorihisa Kotobuki, Eiji Kiyohara, Hiroyuki MurotaAbstract:Annular erythema has been recognized to be a specific, cutaneous Manifestation associated with Sjögren’s syndrome. Based on a search of the literature up to 2007, annular erythema with Sjögren’s syndrome (AESS) preferentially occurs in Asian but not in Western populations. However, the precise clinical course and standard regimen for the management of AESS have remained obscure, primarily because of its rare occurrence in Western populations and the fact that most Asian cases are isolated reports. In this study, 28 cases of AESS from our department and 92 cases distilled from the literature were enrolled in a retrospective study to evaluate the clinical characteristics and most desirable management of this Skin Manifestation in Sjögren’s syndrome. We found that 75% of all cases with AESS were positive for both anti-SSA and anti-SSB antibodies. Multiple therapeutic options are available to treat AESS, including oral steroids. Several anti-malaria drugs or tacrolimus ointment have also been reported to be effective against AESS. AESS is a distinct clinical entity, and a small dose of prednisolone (approx. 10 mg) is sufficient to control diseases activity, except in some cases with systemic Manifestations, and this treatment has a more rapid clinical effect than topical steroids.
-
Annular erythema associated with Sjögren's syndrome: review of the literature on the management and clinical analysis of Skin lesions.
Modern rheumatology, 2010Co-Authors: Ichiro Katayama, Yorihisa Kotobuki, Eiji Kiyohara, Hiroyuki MurotaAbstract:Annular erythema has been recognized to be a specific, cutaneous Manifestation associated with Sjogren’s syndrome. Based on a search of the literature up to 2007, annular erythema with Sjogren’s syndrome (AESS) preferentially occurs in Asian but not in Western populations. However, the precise clinical course and standard regimen for the management of AESS have remained obscure, primarily because of its rare occurrence in Western populations and the fact that most Asian cases are isolated reports. In this study, 28 cases of AESS from our department and 92 cases distilled from the literature were enrolled in a retrospective study to evaluate the clinical characteristics and most desirable management of this Skin Manifestation in Sjogren’s syndrome. We found that 75% of all cases with AESS were positive for both anti-SSA and anti-SSB antibodies. Multiple therapeutic options are available to treat AESS, including oral steroids. Several anti-malaria drugs or tacrolimus ointment have also been reported to be effective against AESS. AESS is a distinct clinical entity, and a small dose of prednisolone (approx. 10 mg) is sufficient to control diseases activity, except in some cases with systemic Manifestations, and this treatment has a more rapid clinical effect than topical steroids.
-
seborrheic area erythema as a common Skin Manifestation in japanese patients with dermatomyositis
Dermatology, 2008Co-Authors: Naoko Okiyama, Ichiro Katayama, Hitoshi Kohsaka, N Ueda, Takahiro Satoh, Kiyoshi Nishioka, Hiroo YokozekiAbstract:Background: Although dermatomyositis (DM)-associated facial erythema was noted in the nasolabial folds of Japanese patients, DM-associated facial erythema other than heliotrope rash has drawn little attention in previous studies. Objectives: To characterize phenotypical features and frequencies of erythema, especially those in the seborrheic area of the head, in DM patients. Methods: A retrospective study on Skin Manifestations in 33 DM patients followed up at our department during the past 15 years was conducted. Results: Macular violaceous erythema (MVE) in the seborrheic area of the face was most frequent (67%). Patients with facial MVE had also MVE in the scalp significantly more frequently than those without facial MVE. The pathology of the facial MVE was dominated by DM-associated changes with slight changes compatible with seborrheic dermatitis (SD). Conclusions: Japanese DM patients had MVE frequently in the seborrheic area of the head. Its phenotypical features suggested that it might be triggered by SD.
